Analysts See $-0.19 EPS for Fennec Pharmaceuticals Inc. (FRX)

March 15, 2018 - By Dolores Ford

 Analysts See $ 0.19 EPS for Fennec Pharmaceuticals Inc. (FRX)

Analysts expect Fennec Pharmaceuticals Inc. (TSE:FRX) to report $-0.19 EPS on March, 29.They anticipate $0.08 EPS change or 72.73 % from last quarter’s $-0.11 EPS. After having $-0.19 EPS previously, Fennec Pharmaceuticals Inc.’s analysts see 0.00 % EPS growth. The stock increased 0.33% or $0.04 during the last trading session, reaching $12.11. About 200 shares traded. Fennec Pharmaceuticals Inc. (TSE:FRX) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. The company has market cap of $223.51 million. The Company’s lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. It currently has negative earnings. The firm was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

More notable recent Fennec Pharmaceuticals Inc. (TSE:FRX) news were published by: which released: “Fennec Pharma’s lead product candidate shows treatment benefit in late-stage …” on September 13, 2017, also with their article: “Otonomy’s $525 Million Dive Is Fennec’s Good Fortune” published on November 02, 2017, published: “Wedbush Starts Fennec Pharmaceuticals (FENC) at Outperform” on March 12, 2018. More interesting news about Fennec Pharmaceuticals Inc. (TSE:FRX) were released by: and their article: “Essetifin Announces Acquisition of Additional Shares of Fennec Pharmaceuticals …” published on May 17, 2016 as well as‘s news article titled: “Fennec Pharmaceuticals Announces Listing on the Nasdaq Capital Market” with publication date: September 11, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.